Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
Clinical trial NCT00193063 · COMPLETED
Trial details
- NCT number
- NCT00193063
- Sponsor
- SCRI Development Innovations, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2001-07-01
- Primary completion
- 2009-05-01
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.